Amgen
Amgen is a Series A to Series C stage investment firm. It has made 11 investments. Their most common stage is series-b (43% of deals). Average disclosed round size is $74.1M (across 11 rounds with reported amounts).
Portfolio
11
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Team
Tyler Jacks
David H. Koch Professor of Biology, Massachusetts Institute of Technology and Founding Director of the David H. Koch Institute for Integrative Cancer Research
Charles M. Holley, Jr.
Former Executive Vice President and Chief Financial Officer of Walmart Inc.
Derek Miller
Senior Vice President, Human Resources
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
14 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 BioAge | Series C | $170M | Feb 2024 |
 Neumora | Series B | $112M | Jan 2022 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
| VVigil | Series B | — | Jan 2021 |
 Science 37 | Series B | $40M | Aug 2020 |
 SomaLogic | Series A | $121M | Jan 2020 |
| Science 37 | Unknown | $40M | Jan 2020 |
| Science 37 | Series A | $6.5M | Oct 2015 |
| ZZiarco | Series B | $33.1M | Jan 2014 |
 Carmot Therapeutics | Series C | $47M | — |
| AARDELYX | Series B | $30M | — |
| EEnlaza | Series A | $100M | — |
 BioClec | Unknown | — | — |
| VVigil | Series A | — | — |
Top Co-Investors
Amgen Ventures7 shared
Redmile Group5 shared
Novartis Venture Fund4 shared
GV4 shared
Mubadala Ventures4 shared
Atlas Venture3 shared
Sanofi Ventures3 shared
Glynn Capital3 shared
Lux Capital3 shared
LifeSci Venture Partners3 shared
Sofinnova Partners2 shared
Logos Capital2 shared
Soleus Capital2 shared
Foresite Capital2 shared
The Column Group2 shared
RA Capital Management2 shared
New Enterprise Associates2 shared
Bristol Myers Squibb2 shared
Surveyor Capital2 shared
Deep Track Capital2 shared
Last updated: 20 October 2026